Glenmark unveils generic version of Gilenya Capsules in US
Mumbai: Drugmaker Glenmark Pharmaceuticals Inc., USA, has recently announced the launch of Fingolimod Capsules, 0.5 mg in the US. The product is a generic version of Gilenya Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
MS is a progressive chronic inflammatory and neurodegenerative disease of the central nervous system (brain and spinal cord) that can drastically affect an individual's everyday life and requires life-long treatment. The disease has a wide range of symptoms, beginning with blurred vision, fatigue, weak limbs, unsteadiness, and tingling sensations and leading to limited mobility and neurological decline.
Medical Dialogues team had earlier reported that the U.S. Supreme Court had turned down Novartis' bid to block the launch of generic versions of the company's blockbuster multiple sclerosis drug Gilenya in a dispute with China's HEC Pharm Co Ltd and other generic drugmakers.
Read also: US Supreme Court turns down Novartis bid to block launch of multiple sclerosis drug Gilenya generics
Read also: Glenmark Pharma unveils Teneligliptin plus Dapagliflozin FDC for type 2 diabetes
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd